Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About American CryoStem Corp
American CryoStem Corp. is engaged in the development, market, and licenses patented adipose tissue-based cellular technologies, bio-materials, and related proprietary services. The company is headquartered in Eatontown, New Jersey and currently employs 6 full-time employees. The company went IPO on 2010-10-02. The firm has developed adipose tissue-derived technologies (Adult Stem Cells) for the fields of regenerative and personalized medicine. Its technologies are the basis for the chemistry, manufacturing, and controls (cGMP Manufacturing) of its ATCell autologous cellular therapy product for use in clinical investigations for biologic license applications with the United States Food and Drug Administration (FDA). The firm has developed and refined its pipeline around its cellular product, ATCell, for clinical therapeutic use. The Company’s ATCELL cell lines are cultured in its patented ACSelerate cell culture media. Its CELLECT service is the required platform for the collection and transportation of live adipose tissue samples to its processing facility. Its ACSelerate cell culture media products are manufactured using patented cell culture media for growing human stromal cells. The firm also includes ATGRAFT services.
Industry: Services-Misc Health & Allied Services, NEC Peers: Bone Biologics Corp Protagenic Therapeutics, Inc.\new NeuBase Therapeutics, Inc. Eterna Therapeutics Inc. Skye Bioscience, Inc. Qualigen Therapeutics, Inc. Transcode Therapeutics, Inc.
